Search

Your search keyword '"Strazzabosco, M."' showing total 1,295 results

Search Constraints

Start Over You searched for: Author "Strazzabosco, M." Remove constraint Author: "Strazzabosco, M."
1,295 results on '"Strazzabosco, M."'

Search Results

2. Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma

3. European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care

5. Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention

6. The Neglected Role of Bile Duct Epithelial Cells in NASH

7. Tumor microenvironment and immunology of cholangiocarcinoma

8. Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma

9. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

11. Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma

14. Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study

16. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study

19. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

20. Congenital cystic lesions of the biliary tree

21. Cholangiocarcinoma

22. Fibrocystic liver disease: Novel concepts and translational perspectives

23. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

24. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

25. Pathological characteristics of liver sinusoidal thrombosis in COVID-19 patients: A series of 43 cases

26. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy

27. Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology

28. Cholangiocyte biology and pathobiology

29. Liver Matrix in Benign and Malignant Biliary Tract Disease

30. The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases

31. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

32. Introduction to the Physiology, Immunology and Pathology of the Liver and Biliary Tree

34. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota

35. Animal models of cholestasis: An update on inflammatory cholangiopathies

36. The challenges of primary biliary cholangitis: What is new and what needs to be done

37. Fibrocystic liver disease

38. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

39. Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases

40. Cholangiocyte pathobiology

41. Modeling of implementation of the new Organ Procurement and Transplantation Network/United Network for Organ Sharing policy for patients with hepatocellular carcinoma

42. The tumour microenvironment and immune milieu of cholangiocarcinoma

43. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

45. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic

46. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

47. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

48. Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes 11 Medical and Health Sciences 1103 Clinical Sciences

49. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

50. Animal models of cholangiocarcinoma: What they teach us about the human disease

Catalog

Books, media, physical & digital resources